esomeprazole + tripotassium dicitrate bismuthate + tetracycline + metronidazole

This is a fixed-dose combination therapy consisting of four active pharmaceutical ingredients: - **Esomeprazole** (a proton pump inhibitor) - **Tripotassium dicitrate bismuthate** (a bismuth salt, also known as bismuth subcitrate potassium) - **Tetracycline** (a tetracycline-class antibiotic) - **Metronidazole** (a nitroimidazole-class antibiotic) The combination is used primarily for the eradication of *Helicobacter pylori* infection and the treatment or prevention of peptic ulcer disease. This regimen is often referred to as "bismuth quadruple therapy" and is recommended in clinical guidelines for patients with H. pylori infection, especially in areas with high rates of clarithromycin resistance or after failure of other regimens[4][6][8]. Esomeprazole reduces gastric acid secretion, enhancing the effectiveness of antibiotics; tripotassium dicitrate bismuthate exerts bactericidal effects against H. pylori and protects the gastric mucosa; tetracycline inhibits bacterial protein synthesis; metronidazole disrupts DNA synthesis in anaerobic bacteria including H. pylori[1][5][6][8].

Other names

5-day quadruple therapyBismuth-containing quadruple therapyBismuth quadruple therapyQuadruple therapy